UFL1‐Mediated UFMylation of ENO1 Restrains Aerobic Glycolysis and Colorectal Cancer Progression
Advanced Science · 2026-10 · 13 (59)
DOI: 10.1002/advs.76875 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 29.07.2026. Verfasst von Xiuqing Ma und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecule…. Hauptthemen laut MEDLINE: Phosphopyruvate Hydratase, Colorectal Neoplasms, DNA-Binding Proteins, Tumor Suppressor Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangdong Major Project of Basic and Applied Basic Research, Science and Technology Project in Guangzhou, National Natural Science Foundation of China.
Abstract (Originalsprache)
Metabolic reprogramming toward enhanced aerobic glycolysis is a hallmark of cancer, yet the contribution of ubiquitin‐like modifications to this process remains poorly understood. Here, we identify the UFMylation E3 ligase UFL1 as a critical suppressor of glycolytic metabolism and colorectal cancer (CRC) progression. Mechanistically, UFL1 directly interacts with the glycolytic enzyme enolase 1 (ENO1) and catalyzes its UFMylation at lysine residues K285 and K420. This modification disrupts ENO1 dimerization, attenuates its enzymatic activity, and consequently suppresses glycolytic flux. Functionally, UFL1‐mediated UFMylation inhibits tumor growth both in vitro and in vivo. Notably, pharmacological enhancement of the UFL1‐ENO1 interaction using the FDA‐approved antibiotic torezolid significantly potentiates the antitumor efficacy of 5‐fluorouracil (5‐FU) across multiple preclinical models, including CRC patient‐derived organoids and xenografts, without detectable toxicity. Collectively, these findings identify ENO1 as a direct substrate of UFMylation, establish UFMylation as a previously unrecognized regulator of cancer metabolic reprogramming, and highlight the UFL1‐ENO1 axis as a promising therapeutic target for colorectal cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Pharmacy, Jinan Univer…
- Department of Dermatology and Venereology, Peking University First Hospital, Peking University, Beijing, China.
- School of Pharmacy, Lanzhou University, Lanzhou, China.
- Guangdong Engineering Research Center of Chinese Medicine and Disease Susceptibility, College of Pharmacy, Jinan University, Guangzhou, China.
- College of Life Science and Technology, Jinan University, Guangzhou, Guangdong, China.
- Guangdong Provincial Engineering Technology Research Center for Innovative Drugs and Bioproducts, School of Pharmacy, Guangdong Medical University, Dongguan, Guangdong, China.
ORCID-Profile: Rong-Rong He, Yang Zhou, Shao-Hua Wang
Förderung
- Guangdong Major Project of Basic and Applied Basic Research
- Science and Technology Project in Guangzhou
- National Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
- Provincial-Municipal Joint Fund Project of Guangdong Basic and Applied Basic Research Fund
- Science and Technology Program of Gansu Province
- Excellent Graduate Student Cultivation Program of Jinan University
- Gansu Provincial Department of Education: 2026 Graduate Innovation Star Project
Zitieren
APA
Ma, X., Wan, R., Zhong, Y., Cui, Z., Zhang, X., He, X., Wang, R., Huang, L., Sun, W. Y., He, R. R., Zhou, Y., Li, J., Shen, L., Wang, S. H., & Liu, T. (2026). UFL1‐Mediated UFMylation of ENO1 Restrains Aerobic Glycolysis and Colorectal Cancer Progression. Advanced Science, 13(59). https://doi.org/10.1002/advs.76875
Vancouver
Ma X, Wan R, Zhong Y, Cui Z, Zhang X, He X, et al. UFL1‐Mediated UFMylation of ENO1 Restrains Aerobic Glycolysis and Colorectal Cancer Progression. Advanced Science. 2026;13(59). doi:10.1002/advs.76875
BibTeX
@article{Ma2026,
author = {Ma, Xiuqing and Wan, Rui and Zhong, Yueyuan and Cui, Ziyang and Zhang, Xuan and He, Xiaoqiang and Wang, Rong and Huang, Lei and Sun, Wan-Yang and He, Rong-Rong and Zhou, Yang and Li, Jianshuang and Shen, Li and Wang, Shao-Hua and Liu, Tongzheng},
title = {UFL1‐Mediated UFMylation of ENO1 Restrains Aerobic Glycolysis and Colorectal Cancer Progression},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {59},
doi = {10.1002/advs.76875}
}
EUVIMED